A Guide to Recombinant Nanobody Expression Service: Workflow, Expression Systems, and Purification

A recombinant nanobody expression service produces a selected nanobody from its gene sequence, then purifies and checks the resulting protein according to an agreed project specification. The usual workflow is sequence review, expression-system selection, small-scale expression, scale-up if needed, purification, and quality-control testing. For veterinary medicine projects, the service brief should also define the intended use, such as research assay development, antigen detection, or exploratory therapeutic research, because application requirements affect construct design and acceptance criteria.

View Details

Nanobodies are commonly described as single-domain antibody fragments of about 12–15 kDa, with a sequence typically around 110–130 amino acids. These are approximate ranges, not product specifications; sequence features and construct design can change the final molecular weight and behavior. This guide explains how to evaluate the workflow, expression options, purification plan, and supplier fit before requesting a quote.

Who This Guide Is For

This guide is for biotechnology companies, veterinary diagnostic developers, research laboratories, and procurement teams evaluating outsourced nanobody production. It is especially relevant when a project already has a nanobody sequence but lacks the expression capacity, purification expertise, or analytical resources to produce the protein in-house. It can also help teams compare proposals from suppliers on a like-for-like basis.

If you have not yet identified a nanobody sequence, expression is only one part of the project. You may need discovery, screening, sequence confirmation, and functional characterization before production can begin. Make clear to a prospective supplier whether you need expression of a supplied sequence or support beyond expression.

How Recombinant Nanobody Expression Works

1. Sequence and project review

The supplier reviews the amino acid or nucleotide sequence, intended application, requested quantity, and any required construct features. These may include a purification tag, cleavage site, secretion signal, or specific terminal residues. Sequence review can identify potential concerns such as unusual cysteine content, hydrophobic regions, or a tag arrangement that could affect downstream use, although these observations do not by themselves predict expression success.

For veterinary applications, describe the target species, sample type, and assay format where relevant. A nanobody intended for an in vitro diagnostic reagent may have different requirements from one being evaluated in a research model. Clarifying the use case helps the supplier propose appropriate purity, buffer, and characterization options without implying regulatory suitability.

2. Expression-system selection and pilot expression

The supplier selects a host and construct strategy based on the sequence, product format, and project requirements. A small-scale pilot can help compare expression or recovery before a larger production run is committed. Pilot results should be interpreted in context: soluble yield, aggregation, and purification recovery are sequence- and process-dependent, so a pilot is a decision tool rather than a guaranteed forecast of final yield.

For a straightforward research-grade single-domain protein, bacterial expression is often considered because the workflow can be relatively direct. If the protein requires eukaryotic processing, secretion, or other specialized features, a supplier may recommend a different host. The choice should be explained in terms of the construct and intended product, not presented as a universally superior system.

3. Scale-up, purification, and formulation

After the pilot or feasibility review, the supplier produces the agreed quantity and purifies the target protein. Depending on the construct, a typical process may use affinity capture through a tag, followed by tag removal or a polishing step such as size-exclusion chromatography. The purification plan should specify whether the deliverable is tag-free or tag-bearing, and whether the final buffer is compatible with your assay or storage conditions.

Ask how the supplier will handle aggregation, low recovery, or a product that does not meet the agreed specification. A 0.22 µm filtration step may be suitable for some preparations, but it should not be assumed to be part of every process or to remove all impurities. Any filtration, concentration, or buffer-exchange step should be confirmed against the intended use and the protein’s behavior.

For more information, please visit NBbiolab.

4. Quality control and delivery

Request a quality-control plan before production starts. Common checks may include protein concentration, apparent molecular weight by electrophoresis, and purity assessment; additional methods can be discussed when the application requires them. Endotoxin testing, aggregation analysis, identity confirmation, or functional testing may be relevant, but availability and acceptance limits should be explicitly agreed rather than assumed.

Ask for a certificate or report that identifies the methods used, results, sample quantity, and storage or handling recommendations. A reported purity value is meaningful only when the method and calculation basis are clear. For veterinary diagnostic development, functional testing in the relevant assay may be more informative than purity alone, but assay development and validation are separate scopes unless included in the quotation.

Expression-System Options

These are broad planning categories, not promises that a particular sequence will express successfully in a given host. A supplier should explain the trade-offs for your sequence and offer a feasibility plan when the outcome is uncertain. If a host choice is driven by a required modification or assay compatibility, document that requirement in the project specification.

Matching the Service to the Application

For a research reagent or early assay-development project, a suitable deliverable may be purified nanobody with concentration, purity assessment, and basic identity information. Diagnostic development may call for additional functional testing in the intended assay, stability evaluation, or comparison across relevant sample matrices. These items should be scoped separately because a protein-production service does not automatically establish diagnostic performance.

For veterinary medicine, clearly distinguish research use from clinical or commercial diagnostic use. Species and sample matrix can influence assay design, and performance in one context does not establish performance in another. Ask the supplier what the expression service covers and plan any regulatory, analytical validation, or clinical evaluation as separate work unless expressly included.

Buyer Selection Framework

Define the deliverable before comparing quotes

Specify the sequence, construct format, desired quantity, purity target, buffer, tag status, and intended application. Quantities such as 1 mg or 5 mg can be useful planning examples, but the required amount should be based on your assay consumption, repeat testing, and expected development stages. Include whether you need a pilot, scale-up, or multiple variants so proposals are compared on the same scope.

Review technical and commercial assumptions

Ask which expression host is proposed, whether a pilot is included, what purification steps are planned, and which quality-control methods will be reported. Request the expected timeline as a project-specific estimate, with dependencies such as sequence review, construct synthesis, and customer approval identified. Pricing, minimum order quantities, and lead times vary with host, scale, sequence behavior, and testing requirements; they cannot be reliably inferred from the phrase “nanobody expression” alone.

Check ownership, documentation, and support

Confirm how sequence confidentiality, material transfer, data ownership, and leftover material will be handled. Ask whether the supplier provides troubleshooting support if expression is low or the purified protein does not meet an agreed criterion. A transparent proposal should separate included work from optional testing and describe how deviations or scope changes are managed.

Common Pitfalls to Avoid

• Requesting only a mass quantity: A quantity without purity, buffer, and tag requirements can produce an unsuitable deliverable.
• Assuming all nanobodies behave alike: Solubility and recovery are sequence-dependent, so ask whether feasibility testing is appropriate.
• Equating purity with function: Analytical purity does not demonstrate binding or performance in a veterinary assay.
• Leaving the use case vague: The intended assay or downstream step can determine which tests and formulation choices are useful.
• Comparing headline prices only: Check whether construct preparation, pilot work, purification, testing, and shipping are included.

Key Takeaways

• Recombinant nanobody expression typically proceeds from sequence review through host selection, pilot expression, production, purification, and quality control.
• Bacterial, yeast, and mammalian systems have different possible advantages; selection should be based on sequence and intended use rather than a universal ranking.
• Purity, identity, aggregation, endotoxin, and functional testing are distinct quality questions. Agree on the relevant tests and acceptance criteria in advance.
• Price, minimum quantity, and lead time depend on the project scope and sequence behavior, so request a written, itemized proposal.

Conclusion: Preparing an Expression-Service Request

A recombinant nanobody expression service can take a confirmed sequence through production and purification, but the right workflow depends on the construct, application, and required evidence of product quality. For veterinary medicine projects, define whether the protein is a research reagent, an assay-development component, or part of a broader diagnostic program before selecting a host or requesting a quote. This prevents buyers from treating expression, functional validation, and regulatory readiness as interchangeable deliverables.

To move forward, prepare the sequence and a concise specification covering quantity, tag format, buffer, intended use, quality-control requirements, and desired timeline. NBbiolab can review these inputs, discuss suitable expression and purification options, and clarify which testing is included in a proposed scope. Contact us with your project requirements to request a feasibility assessment and quotation.

Are you interested in learning more about Recombinant Nanobody Expression Service? Contact us today to secure an expert consultation!